Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
One thing that I was clued in on Twitter about was on the program guide page for 11/19: https://www.eventscribe.net/2021/SNO/agenda.asp?startdate=11/19/2021&enddate=11/19/2021&BCFO=&pfp=days&mode=&fa=&fb=&fc=&fd=
There is no mention of Linda Liau or any presentations involving her for that matter. However, when you pull up the source code (you can hit control+U if you are using a Chrome-based browser) and search the source code, there are 12 references to Linda Liau using 'hidden' styling elements. I'm trying to see if there is any way that I can decipher these relating to a specific presentation.
Interesting if anything else. I'll post any updates in my follow ups.
He has a total of:
J. Cofer Black - Virginia Metro Area - Options: 5,888,251
(As of 5/21)
Personally I don't think this will dip below .98. There is so much support at that .98/.99 mark.
Agree 100%. I don't think there are many legitimate shorts in the conversation at the moment. What I think we are seeing with the SP is just MM manipulation and weak holders being shaken out.
I'm open to being wrong on this, but based on what we know in totality, based on the language in the 10Q around extensions of 2-4 month timeframes which were not in previous 10-Q's, I think the likelihood of any news at SNO is lower.
I do think we will have news in the next 2-4 months however.
2.36 million shares traded today; 10-day average is 1.57 million. Interesting to see this type of downtrend given all we know.
Agree @ATL
I was just reading the 10-Q and I noticed this paragraph. In the second paragraph is what really caught my eye. Extension of the notes to 2-4 months with individual lenders. Two thoughts:
1) It's clear that there is an expectation of something happening in 2-4 months.
2) I wonder if this is why Bigger was in Bethseda in early October.
"During October 2021, the Company entered into multiple four-month note agreements (the “Notes”) with various individual lenders (the “Holders”) with an aggregate principal amount of $1.14 million for net proceeds of $1.1 million. The Notes contain a conditional piggy-back right to independently purchase shares from the Company, which provides a right for the Holders, contingent on the release of clinical trial data and the next private placement offering (“Next Offering”) after this release, to (a) purchase shares from the Company within seven days following such Next Offering at a 12% discount from the share price of the Next Offering for a variable number of shares equal to an amount up to 50% of the principal amount of the loan and (b) exchange some or all of the outstanding loan amount for a variable number of shares, within seven days after the Next Offering at a 12% discount, resulting in a reduced cash amount repayable under the loan agreement.
In October 2021, the Company entered into multiple note extension agreements whereby the maturity date of the notes was extended for additional 2-4 months."
Thanks for clarification, I missed this header in the document.
Thanks AE for doing the work on that. I think it would be better news if this was the first posting of it, but still important insight in the grand scheme.
I did not catch this the first time around @ATL - good find and call out.
Have you yet gone back to see if this language was included in any of the previous 10-Q updates? If not, then this is the most meaningful update in this 10-Q and great news, IMO.
Thanks Jerry.
The extension to 11/30 is not anything of significance as I understand. The reason it's stated that way is because of the policy that was put in place that all executives need to give 60 days notice in order to exercise their warrants; and since this 10-Q is as of 9/31, 11/30 would be the earliest date that these can be exercised as noted in the 10-Q:
For reference:
RE: KP - I was the one that solicited that feedback from her, hoping to craft something that would give us just enough 'hope' without asking her to cross the line. That "… and I really like my new job" was incredibly telling to me and so wisely worded on her part.
Accumulation/selling in the 1.04-1.05 range appears to be completed. Let's see this walk back up by EOD for 1.10-1.20 finish.
Yeah - I received notification that they would post today on my broker, after market hours.
Flip, you have made some of the most logical, concise, well explained arguments I've have ever read anywhere, period. Thank you for being you.
10 thumbs up. Good to see your name again GGB!
@Sojo where you at on a price prediction today
I can't comment on the legal aspects of this but she owns tens of millions of shares and warrants already. She will likely be a multi-billionaire when this comes fully to fruition.
I'll tell you what ex, I like your sentiment lately. Welcome to the long and strong side. You're not so bad afterall
Flipper I am starting to think you and Mr.Bigger have a lot in common.. hmm. :P
Perspective.
Make sure you hold me accountable to that! I expect a PM with your address the minute TLD hits.
Lol - I was getting worried about your negativity there for a while PoorMan. Glad you're back. I will send you an Omaha steak when they release TLD. Deal?
Great find. This sounds interesting:
7:40 AM – 8:00 AM EST Transcriptional Signature of Anti-Tumor Immune Responses Induced by Neoadjuvant Immunotherapy in Primary and Metastatic Brain TumorsThis session will NOT have CME.
Concurrent Speaker: Robert M. Prins, BS, MS, PhD – UCLA
We missed you the last few days buddy. Great to have you back and 100% agree. This is a platform treatment, which we already know is successful. The only thing any one can argue is potentially a trial design flaw (which we know is unlikely thanks to @ATLnsider's DD) or the potential of a repeat phase 3 also very unlikely. Anyone that is pulling out their investment at this price probably should be invested in biotech or maybe whatsoever.
It is a struggle for sure to watch the investment drop in the red, but you don't lose anything until you sell :)
I bought as much as I can until Friday on my next pay check where I will add another couple thousand.
I have not seen a single reason from you that lays out any logical argument "in detail". Please link to those posts and maybe I'll Venmo you a few hundred bucks when TLD drops on your head like in one of those old cartoons LOL
I should of clarified my question around external controls with;
'have there been any trials where the treatment has become the SOC that have come before us and have leveraged external controls'
@flipper44 - this is an awesome post and extremely undervalued information by the investor community if you ask me.
Question for you - have there been any significant trials that have come before us that have use external controls? Or are we the first. I know there are at least 1 or 2 active ongoing trials that are structured this way, but my question is around past completed trials.
Also - have you read this document that was published a few months back? https://link.springer.com/article/10.1007/s43441-021-00302-y - This is a really well written and captures NWBO's trial at heart.
This is my favorite part of that paper:
One of your better posts Happy. I picked up another 1K shares today and will do so again at the end of the week if the price remains this low.
Great to see your name again Cherry!
The point that is being missed here is that it doesn't really matter who profits if Advent is sold. Advent is likely a huge unnecessary complication and distraction for NWBO to have any capital or operational ownership of. Advent is just a necessary part of the puzzle for regulatory approval and for DC-Vax to be a success. It's even less of a point if Flaskworks is successful because then NWBO shareholders will own the whole process, end to end and be likely receiving compensation in some fashion for the use of the technology. I don't understand the neverending argument on this. The only thing we should be worried about is successful TLD which we all know that worrying is "needless" ;)
Senti- can you link to the filing that shows this?
LOL! It will be awesome when news finally breaks on this. Maybe in 5 years from now, we can get book written by LP to hear about her journey of what was actually going on during this time frame.